Anthem’s ER policy called ‘dangerous,' ‘unfair to patients’

In an effort to steer patients toward less expensive sites of care, Anthem has instituted policies in several states that if an emergency room (ER) visit is determined to be unnecessary, they may end up footing the bill—something 34-year-old Allison Wrenne learned the hard way.

When abdominal pain forced her to the floor one morning, her neighbor—a physician assistant—told her to go to the ER. She was diagnosed with a ruptured ovarian cyst. In Anthem’s opinion, that wasn’t an emergency, so Wrenne was sent a bill for $4,110.

“How are you supposed to know that?” she told the Associated Press. “I’m not a doctor ... that’s what the emergency room is for.”

While physicians agree ER isn’t the right option for many minor injuries, they’re concerned this Anthem policy will scare patients away from going there for real emergencies out of fear of receiving a hefty bill. Jesse Pines, MD, an emergency medicine professor at George Washington University, called it the policy “totally unfair to patients.”

A recent study found only 3.3 percent of ER visits between 2005 and 2011 could be classified as avoidable, calling into question limiting ER access as a strategy to prevent overutilization.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.